Hoth Therapeutics, Inc. (HOTH), Thursday announced promising data from the first human treatment of epidermal growth factor receptor inhibitor or EGFRI-associated papulopustular eruptions with its novel therapeutic HT-001.
During the study, the company reported significant improvement within one week of initiating therapy in a 59-year-old female undergoing treatment for metastatic breast cancer.
The biotechnology company has also initiated a Phase 2a clinical trial to further evaluate the efficacy and safety of HT-001 in the treatment of EGFRI-associated skin toxicities.
Currently, Hoth's stock is trading at $1.32, up 90.04 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.